Monoamine oxidases and tobacco smoking
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Although nicotine has been identified as the main ingredient in tobacco responsible for aspects of the tobacco dependence syndrome, not all of the psychopharmacological effects of smoking can be explained by nicotine alone. Accumulating preclinical and clinical evidence has demonstrated that smoking also leads to potent inhibition of both types (A and B) of monoamine oxidase (MAO). Smokers have 30-40 % lower MAOB and 20-30 % lower MAOA activity than non-smokers. Reduced MAO activity in smokers has been shown by direct measures (platelets, positron emission tomographic studies) or by indirect measures (concentration of monoamine catabolites in plasma or CSF). We examine the hypothesis that chronic habitual smoking can be better understood in the context of two pharmacological factors: nicotine and reduced MAO activity. We speculate that MAO inhibition by compounds found in either tobacco or tobacco smoke can potentiate nicotine's effects. Based on this concept, more effective anti-smoking drug strategies may be developed. As a practical consequence of tobacco smoke's MAO-inhibitory properties, comparative psychiatric research studies need to screen and control for tobacco use.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation
Jorenby, D. E., Leischow, S. J., Nides, M. A., Rennard, S. I., Johnston, J. A., Hughes, A. R., Smith, S. S., Muramoto, M. L., Daughton, D. M., Doan, K., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903043400903 · Cited by 1,585 · cited 2×
“In support of our hypothesis, the best results obtained to date have occurred with the co-administration of bupropion and the nicotine patch, which was found to be more effective than the patch alone (Jorenby et al., 1999).”
BackgroundResultNicotine replacement therapy for smoking cessation
Silagy, C., Lancaster, T., Stead, L., Mant, D., & Fowler, G. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000146.pub2 · Cited by 972
Mortality from smoking worldwide
Peto, R., Lopez, A. D., Boreham, J., Thun, M., Heath, C., & Doll, R. (1996) · British Medical Bulletin · doi:10.1093/oxfordjournals.bmb.a011519 · Cited by 638 · cited 1×
“The average loss of life attributable to tobacco in 1990 was about 16 years (Peto et al., 1996).”
BackgroundMeta-analysis on efficacy of nicotine replacement therapies in smoking cessation
Silagy, C., Mant, D., Fowler, G., & Lodge, M. (1994) · The Lancet · doi:10.1016/s0140-6736(94)90933-4 · Cited by 481
McKenna, D. J., Towers, G. H. N., & Abbott, F. (1984) · Journal of Ethnopharmacology · doi:10.1016/0378-8741(84)90003-5 · Cited by 398 · cited 1×
“DMT ingested orally is inactive because the compound is degraded by visceral stores of MAO; however, ingestion of β-carbolines together with DMT increases the latter drug’s bioavailability and leads to hallucinogenic effects (McKenna et al., 1984).”
BackgroundNortriptyline and Cognitive-Behavioral Therapy in the Treatment of Cigarette Smoking
Hall, S. M., Reus, V. I., Muñoz, R. F., Sees, K. L., Humfleet, G., Hartz, D. T., Frederick, S., & Triffleman, E. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.8.683 · Cited by 385 · cited 2×
“The therapeutic effectiveness of bupropion (a NE and DA re-uptake blocker), and nortriptyline (mainly a NE re-uptake blocker) as smoking cessation aids has been established in randomized, placebo-controlled trials (Hall et al., 1998 ; Hurt et al., 1997 ; Jorenby et al., 1999 ; Prochazka et al., 1998).”
BackgroundEisenhofer, G., Goldstein, D. S., Ropchak, T. G., Nguyen, H. Q., Keiser, H. R., & Kopin, I. J. (1988) · Journal of the Autonomic Nervous System · doi:10.1016/0165-1838(88)90130-0 · Cited by 98
Cited by
Toxicological effects of dietary biogenic amines.
Ladero, V., Calles-Enriquez, M., Fernandez, M., & A. Alvarez, M. (2010) · Current Nutrition & Food Science · doi:10.2174/157340110791233256 · Cited by 538
Biogenic Amines in Dairy Products
Linares, D. M., Martín, M., Ladero, V., Alvarez, M. A., & Fernández, M. (2011) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2011.582813 · Cited by 399
Monoamine oxidase and cigarette smoking
Fowler, J. S., Logan, J., Wang, G.-J., & Volkow, N. D. (2003) · NeuroToxicology · doi:10.1016/s0161-813x(02)00109-2 · Cited by 251
“We note that another review on this same topic was published recently (Berlin and Anthenelli, 2001).”
BackgroundDucci, F., Enoch, M.-A., Hodgkinson, C., Xu, K., Catena, M., Robin, R. W., & Goldman, D. (2008) · Molecular Psychiatry · doi:10.1038/sj.mp.4002034 · Cited by 229
Functional brain imaging of tobacco use and dependence
BRODY, A. (2006) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2005.04.012 · Cited by 207
“MAO participates in the catabolism of dopamine, norepinephrine, and serotonin (Berlin and Anthenelli, 2001; Fowler et al., 2003a), and it has been postulated that some of the clinical effects of smoking are due to MAO inhibition, leading to decreases in monoamine breakdown with a subsequent…”
Background
Metadata
- Authors
- Berlin, I., & M. Anthenelli, R.
- Venue
- The International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2001-03
- Volume
- 4
- Issue
- 01
- Pages
- 33-42
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- OpenAlex
- W2087896578
- Cited by
- 150
- References
- 7
- FWCI
- 3.50
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Monoamine oxidases and tobacco smoking. https://app.cochat.ai/papers/10.1017/s1461145701002188
- The paper
- Berlin, I., & M. Anthenelli, R. (2001). Monoamine oxidases and tobacco smoking. The International Journal of Neuropsychopharmacology. https://doi.org/10.1017/s1461145701002188
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.